Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy

NCT00749892 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00749892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00749892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2008
Completion date
November 26, 2019
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent bladder urothelial carcinoma, recurrent renal pelvis urothelial carcinoma, recurrent ureter urothelial carcinoma, recurrent urethral urothelial carcinoma, stage 0a bladder cancer ajcc v8, stage 0a renal pelvis cancer ajcc v8, stage 0a ureter cancer ajcc v8, stage 0a urethral cancer ajcc v8, stage 0is bladder cancer ajcc v8, stage 0is renal pelvis cancer ajcc v8, stage 0is ureter cancer ajcc v8, stage 0is urethral cancer ajcc v8, stage ii bladder cancer ajcc v8, stage ii renal pelvis cancer ajcc v8, stage ii ureter cancer ajcc v8, stage ii urethral cancer ajcc v8, stage iii renal pelvis cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iii urethral cancer ajcc v8, stage iiia bladder cancer ajcc v8